You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
Johnson and Johnson
Merck
McKesson

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Perflutren - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for perflutren and what is the scope of freedom to operate?

Perflutren is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Perflutren has forty-one patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for perflutren
International Patents:41
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 34
Clinical Trials: 19
Patent Applications: 2,887
Formulation / Manufacturing:see details
DailyMed Link:perflutren at DailyMed
Recent Clinical Trials for perflutren

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Trust Bio-sonics, Inc.Phase 1
UNC Lineberger Comprehensive Cancer CenterPhase 2
StatPlus,Inc.Phase 1

See all perflutren clinical trials

Pharmacology for perflutren

US Patents and Regulatory Information for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for perflutren

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 0790017-8 Sweden   Start Trial PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 C300267 Netherlands   Start Trial PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 SPC/GB07/031 United Kingdom   Start Trial PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Express Scripts
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.